Naples

• A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax in Combination With Polatuzumab Vedotin Plus Rituximab (R) and Cy … Ended
  2023-507497-40-00 1 2021-05-31 Diffuse large B-cell lymphoma (DLBCL), Grade 3B follicular lymphoma, H
• Non-inferiority study of GSK3511294 (depemokimab) compared with mepolizumab or benralizumab in participants with severe asthma with an eosin … Ended
  2023-510230-84-00 5 2021-05-28 Severe asthma with an eosinophilic phenotype
• Phase 2 study of Pembrolizumab given every 6 weeks to participants diagnosed with Relapsed or Refractory Classical Hodgkin’s Lymphoma (rrcHL … Ended
  2024-510979-38-00 4 2021-05-27 Relapsed or refractory Classical Hodgkins Lymphoma and relapsed or ref
• "A Variable Length Study to Evaluate the Efficacy and Safety of Budesonide/Glycopyrronium/Formoterol inhaler in Adults and Adolescents with … Ended
  2023-505787-11-00 5 2021-04-29 Severe and inadequately controlled asthma
• MK-7684A (new drug co-formulation of pembrolizumab with an anti-TIGIT) plus docetaxel works to help stop or slow down the growth of your non … Ended
  2022-501252-28-00 4 2021-04-15 Non Small Cell Lung cancer
• A study to investigate the novel agent BNT111 and cemiplimab in combination or as single agents in patients with advanced melanoma that has … Ended
  2023-509513-36-00 4 2021-03-24 Melanoma (Stage III and IV)
• Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Ga … Ended
  2023-504834-23-00 11 2021-02-24 Advanced/Metastatic Gastroesophageal Adenocarcinoma
• A Phase 1 Study of TAS0612 in Patients with Locally Advanced or Metastatic Solid Tumors Ended
  2024-515175-35-00 1 2021-02-10 Locally Advanced or Metastatic Solid Tumors
• Study of efficacy and safety of LNP023 in primary IgA nephropathy patients. Ended
  2024-511067-29-00 5 2021-01-25 IgA Nephropathy
• This is a randomized, double-blinded, Placebo controlled trial with a 3-part treatment period that will evaluate the efficacy and safety of … Ended
  2023-503770-21-00 4 2021-01-05 Classic Congenital Adrenal Hyperplasia
• Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants wit … Ended
  2023-508443-40-00 5 2020-12-18 Lung Cancer, Non-Small Cell
• A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine (PIONEER-PEDS2) Ended
  2023-506724-85-00 5 2020-11-19 Migraine
• A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine (PIONEER-PEDS1) Ended
  2023-506253-38-00 5 2020-11-09 Migraine
• Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor tolebrutinib (SAR442168) (PERSEUS) Ended
  2024-514495-41-00 5 2020-11-04 Primary Progressive Multiple Sclerosis
• A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Ravulizumab in Adult and Adolescent Participants who have Thro … Ended
  2023-510107-22-00 5 2020-10-27 Hematopoietic stem cell transplant-associated thrombotic microangiopat
• A Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of Forimtamig in Participants With Relapsed or Refractory Multiple My … Ended
  2023-504571-25-00 3 2020-10-20 Relapsed or Refractory Multiple Myeloma
• A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cel … Ended
  2022-502480-38-00 5 2020-09-09 Non−small cell lung cancer (NSCLC)
• Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants with Melanoma (KEYMAK … Ended
  2023-506313-21-00 9 2020-08-03 PD-1 refractory melanoma
• Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Participants With Programmed Cell-death 1 (PD-1) Refracto … Ended
  2023-506312-41-00 9 2020-07-30 PD-1 refractory melanoma
• Phase 3 Study of Pembrolizumab and Lenvatinib in Combination with TACE for Incurable/Non-metastatic Hepatocellular Carcinoma Ended
  2022-502116-36-00 5 2020-07-10 Incurable/Non-metastatic Hepatocellular Carcinoma
• A Study of Atezolizumab plus Carboplatin and Etoposide with or Without Tiragolumab (Anti-Tigit Antibody) in Patients with Untreated Extensiv … Ended
  2022-502988-37-00 5 2020-06-19 Small cell lung cancer (SCLC)
• A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes (SURPASS-CV … Ended
  2023-507846-96-00 5 2020-06-19 Type 2 Diabetes Mellitus
• A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) (AcceleRET-Lung) Ended
  2023-505035-12-00 5 2020-06-12 RET fusion−positive, metastatic Non-Small Cell Lung Cancer
• A Study of Tiragolumab, an Anti-TIGIT Antibody, in Combination with Atezolizumab Compared with Placebo in Combination with Atezolizumab (an … Ended
  2022-502482-17-00 5 2020-05-19 Non-small cell lung cancer (NSCLC)

Showing 1,105–1,128 of 1,177 trials